Product Information
METHOTREXATE 250 MG/10 ML VIAL is a generic product labeled by Accord Healthcare Inc., priced at $0.7020 per ML under NDC 16729027703. Its NADAC has been published 356 times since May 7, 2014.
FDA first approved this application on Apr 30, 2007. Its Orange Book therapeutic-equivalence code is AP.
Strength
25 mg/mL
Manufacturer
Accord Healthcare Inc.NDC
16729027703
Classification
Generic
Dosage Form
INJECTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
METHOTREXATEApproval Type
Generic (ANDA)
FDA Application
ANDA040716FDA Approved
4/30/2007
TE Code
AP
On Market Since
3/7/2014
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 250 MG/10 ML VIAL has been published 356 times since May 7, 2014, and over the history we have for it it has declined 17.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7020 per ML |
|---|---|
| All-time high | $1.1148 (Jul 15, 2015) |
| All-time low | $0.6670 (Sep 21, 2016) |
| 52-week high | $0.7020 |
| 52-week low | $0.7020 |
| Median price | $0.7998 |
| Average price | $0.7813 |
| Largest weekly change | +42.2% (Jun 22, 2016) |
| Weeks tracked | 356 |
| Tracking since | May 7, 2014 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Accord Healthcare Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 250 MG/10 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 250 MG/10 ML VIAL, manufactured by Accord Healthcare Inc., is $0.7020 per ML (NDC 16729027703), effective Sep 30, 2026.
How has the price of METHOTREXATE 250 MG/10 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has declined 17.8%. It has been tracked across 356 weekly CMS publications since May 7, 2014.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 250 MG/10 ML VIAL?
Since May 7, 2014, the NADAC for METHOTREXATE 250 MG/10 ML VIAL has ranged from a low of $0.6670 (Sep 21, 2016) to a high of $1.1148 (Jul 15, 2015), with a median of $0.7998 per ML.
Are there cheaper alternatives to METHOTREXATE 250 MG/10 ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHOTREXATE 1 GRAM/40 ML VIAL, is $0.6450 per ML — about 8% below METHOTREXATE 250 MG/10 ML VIAL.
Who manufactures METHOTREXATE 250 MG/10 ML VIAL?
METHOTREXATE 250 MG/10 ML VIAL (NDC 16729027703) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.